Mutual of America Capital Management LLC reduced its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC – Free Report) ...

Equities researchers at Zacks Research issued their FY2024 earnings per share (EPS) estimates for Blueprint Medicines in a ...

Blueprint Medicines' AYVAKIT leads its revenue growth, while its pipeline targets multiple cancers. Read why BPMC stock is a ...

JPMorgan initiated coverage of Blueprint Medicines (BPMC) with an Overweight rating and $126 price target Blueprint is a ...

JP Morgan initiated coverage on Blueprint Medicines Corporation (NASDAQ:BPMC), a biotech company focused on modulating immune ...

Needham added Axsome Therapeutics (AXSM) to the firm’s Conviction List while removing Blueprint Medicines (BPMC). Axsome’s lead asset Auvelity should continue to grow in major depressive disorder, ...

Analyst Ami Fadia of Needham maintained a Buy rating on Blueprint Medicines (BPMC – Research Report), retaining the price target of ...

Fintel reports that on November 14, 2024, JP Morgan initiated coverage of Blueprint Medicines (NasdaqGS:BPMC) with a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

马萨诸塞州剑桥市 - 根据最近的SEC文件披露，Blueprint Medicines Corp (NASDAQ:BPMC)的董事Lonnel Coats于11月20日和21日执行了一系列股票交易，其中包括总计约187万美元的销售。

At this time, I would like to welcome everyone to the Blueprint Medicines Third Quarter 2024 Financial Results Conference Call. [Operator Instructions] Thank you. Jenna Cohen, you may begin your ...

Blueprint Medicines (NASDAQ:BPMC) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table summarizes their ...